At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
NeVa VSdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Vesalio Neva VS for the Treatment of Symptomatic Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage (aSAH) (The VITAL Study)
In Brief
A clinical study evaluating NeVa VS for Cerebral Vasospasm. Completed, enrolled 30 participants across 10 sites.
Detailed Summary
The objective of the study is to assess the safety and probable benefit of the Neva VS device in patients presenting with symptomatic cerebral vasospasm despite maximal medical management following aSAH.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCerebral Vasospasm
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartDec 2018
Primary CompletionMay 2021
TodayJul 2026
First PostedAug 2, 2018
Enrollment StartDec 19, 2018
Primary CompletionMay 31, 2021
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 7.9 years ago
Interventions
NeVa VSdevice
mechanical dilatation